Climb Bio, Inc. (CLYM) vs CorMedix Inc. (CRMD)

A side-by-side comparison of Climb Bio, Inc. and CorMedix Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CLYM vs CRMD

growth of $100 · dividends reinvested · last 2y
CLYM +41.1% (+18.8%/yr)CRMD +24.3% (+11.5%/yr)CLYM compounded faster over this window
0100200300Start $10020252026$141$124
CLYM CRMD

CLYM vs CRMD: by the numbers

  • •CLYM is the larger company ($612M vs $571M market cap).
  • •CRMD is profitable (40.49% net margin) while CLYM runs a net loss (0.00%).

Metrics side by side

Valuation

MetricCLYMCRMD
P/E ratioN/A3.42
Forward P/EN/A14.71
P/S ratioN/A1.24
P/B ratio2.551.24
EV / EBITDAN/A1.82
FCF yieldN/A43.82%

Profitability

MetricCLYMCRMD
Gross margin0.00%82.78%
Operating margin0.00%46.95%
Net margin0.00%40.49%
ROE-24.06%40.62%
ROIC-26.94%27.87%

Growth (annualized)

MetricCLYMCRMD
Revenue CAGR (5Y)N/A352.03%
Total return CAGR (5Y)N/A9.70%

Frequently asked

Is CLYM or CRMD more profitable?
CRMD runs the higher net margin — CLYM at 0.00% versus CRMD at 40.49%.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.